Malta-based pharmaceutical firm Pharmacare Premium Ltd is launching Sorafeni, new generic cancer drug
Malta-based pharmaceutical firm Pharmacare Premium Ltd is launching generic Sorafenib, a product used for the treatment of kidney and liver cancers, certain types of leukaemia and advanced thyroid cancer.
Sorafenib was developed at the company’s Hal Far facility in partnership with Greece’s Genepharm and will launch as soon as the patent for the original treatment, called Nexavar, expires in the target countries. More than 20 partners will now begin marketing and selling the product in at least 30 countries from Thailand to Mexico and from Canada to South Africa.
Hani Sarraf, Business Development Director of Pharmacare Premium Ltd, said: “The launch of Sorafenib, our generic version of Nexavar, is a very significant moment for Pharmacare Premium which highlights the quality of our research, development, and manufacturing capabilities. It is also a contribution to the global battle against several types of cancer, making treatments considerably cheaper and more accessible for patients across the globe.”
More information on Pharmacare Premium is available at https://pharmacarepremium.com/
Alexandre Dreyfus, the net entrepreneur behind blockchain and sports pioneers Chiliz and Socios.com, has announced…
The Council of the European Union has endorsed Malta's medium-term fiscal-structural plan. In a statement…
Parliamentary Secretary for Youth, Research and Innovation Keith Azzopardi Tanti, together with Xjenza Malta and…
As the World Economic Forum’s annual gabfest gets into full swing Tuesday, U.S. President Donald Trump gave…
Cruise passenger traffic during Q4 2024 totaled 176,812, marking a 4.6% increase over the same…
Donald Trump was sworn in as the 47th president Monday, returning to power with a…